CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT NO. 3 TO SECOND RESTATED LICENSE AGREEMENTLicense Agreement • August 11th, 2020 • Altimmune, Inc. • Pharmaceutical preparations
This Amendment No. 3 (“Amendment No. 3”) to the Second Restated License Agreement (“License”) is made and entered into on the date of the last signature below by and between:
AMENDMENT NO. 2 TO SECOND RESTATED LICENSE AGREEMENTLicense Agreement • August 11th, 2020 • Altimmune, Inc. • Pharmaceutical preparations
This Amendment No. 2 to the Second Restated License Agreement (this “Amendment No. 2”) is made and effective as of September 20, 2016 by and between Crucell Holland B.V., a corporation organized under the laws of the Netherlands, having offices at Archimedesweg 4-6, 2333 CN Leiden, the Netherlands (“CRUCELL”) and Altimmune, Inc., a Delaware corporation, having offices located at 19 Firstfield Road, Gaithersburg, Maryland, USA 20878, f/k/a VAXIN INC., a Delaware corporation, having offices located at 1500 First Avenue North, Birmingham, Alabama, U.S.A. (“ALTIMMUNE”).
